Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by University of Missouri-Columbia
Sponsor:
Information provided by (Responsible Party):
Paul Fadel, PhD, University of Missouri-Columbia
ClinicalTrials.gov Identifier:
NCT01633814
First received: June 25, 2012
Last updated: June 25, 2013
Last verified: June 2013
  Purpose

Older women have an exaggerated increase in blood pressure during exercise. However, the reasons for this are unclear. It is important to investigate this phenomenon because a greater blood pressure response to exercise has been associated with an increased risk of stroke and mortality in otherwise healthy individuals. A unique aspect of aging in women is the profound change in hormone levels (i.e. estrogen and progesterone) associated with menopause. The influence of changes in estrogen and progesterone levels on the cardiovascular responses to exercise is poorly understood. However, it has been suggested that these hormones might change the responsiveness of the cardiovascular system. Possible mechanisms that could account for these changes are the arterial baroreflex and feedback from the exercising muscle (known as the exercise pressor reflex), both of which are known to powerfully modulate blood pressure during exercise. However, to date, few human studies have thoroughly examined the influence of changes in hormone levels on baroreflex function during exercise or the exercise pressor reflex in older women. As such, the purpose of this research project is to assess baroreflex function and the exercise pressor reflex in older women after transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo.


Condition Intervention
Physiological Processes [G07.700]
Aging [G07.700.320.124]
Exercise [G11.427.590.530.698.277]
Drug: Transdermal estradiol
Drug: Estradiol plus progesterone
Drug: Oral Progesterone
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by University of Missouri-Columbia:

Primary Outcome Measures:
  • Change in carotid baroreflex sensitivity (bpm/mmHg) [ Time Frame: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo. ] [ Designated as safety issue: No ]
    Carotid baroreflex sensitivity will be measured using the application of neck pressure and neck suction. Briefly, a variable neck pressure collar will be placed around the anterior two thirds of the neck to change carotid sinus transmural pressure.

  • Change in exercise pressor reflex responsiveness (mean blood pressure response (mmHg) and muscle sympathetic nerve activity response (burst frequency) during post handgrip ischemia.) [ Time Frame: Within one week prior to and then after one month of transdermal estrogen alone, transdermal estrogen plus progesterone, progesterone alone and placebo. ] [ Designated as safety issue: No ]
    To estimate exercise pressor reflex responsiveness changes in blood pressure and muscle sympathetic nerve activity from rest to during a period of post handgrip ischemia will be used.


Estimated Enrollment: 30
Study Start Date: September 2011
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Transdermal estradiol
Transdermal estradiol, delivery rate 100 µg day-1 plus oral placebo.
Drug: Transdermal estradiol
transdermal estradiol, delivery rate 100 µg day-1 plus oral placebo
Experimental: Estradiol plus progesterone
transdermal estradiol 100 µg day-1 plus oral progesterone (provera 5 mg)
Drug: Estradiol plus progesterone
transdermal estradiol 100 µg day-1 plus oral progesterone (provera 5 mg)
Experimental: Oral Progesterone
placebo patch plus oral progesterone (provera 5 mg)
Drug: Oral Progesterone
placebo patch plus oral progesterone (provera 5 mg)
Placebo Comparator: Placebo
placebo patch plus oral placebo.
Drug: Placebo
placebo patch plus oral placebo.

  Hide Detailed Description

Detailed Description:

Study Design Older postmenopausal women will be randomized, in a double-blinded crossover design, to receive (i) transdermal estradiol, delivery rate 100 µg day-1 plus oral placebo, or (ii) transdermal estradiol 100 µg day-1 plus oral progesterone (provera 5 mg) or (iii) placebo patch plus oral progesterone (provera 5 mg) or (iv) placebo patch plus oral placebo. The experimental measurements and procedures below will be performed before and 4 weeks after each treatment.

Experimental measurements:

Blood Pressure- A blood pressure cuff will be wrapped around the right arm to obtain blood pressure via a standard automated auscultometric device (Welch-Allyn). In addition, beat-by-beat blood pressure will be obtained via finger photoplethysmography (Finapress blood pressure monitor).

Heart Rate- Standard limb lead electrodes will be used to obtain heart rate measurements.

Respiration- An elastic band will be placed around the subject's abdomen to measure rate and depth of breathing.

Blood Samples- A venous catheter will be placed in the subjects arm for blood samples. For screening purposes measurements of glucose, electrolytes, cholesterol and triglycerides will be made. In addition, progesterone, estrogen and testosterone, will be assessed to verify hormonal status.

Sympathetic Nerve Activity- A tiny microelectrode will be placed in the peroneal nerve of the leg, located just below the knee on the outer part of the leg. Alternatively, the median nerve located at the inside of the elbow will be used. At these points the nerves are closest to the surface of the skin. The course of the nerve will be determined by electrically stimulating through the skin with a pencil shaped electrode. When the nerve is stimulated, involuntary twitching and/or tingling sensations of the foot or hand will occur. The twitching or tingling will disappear when the stimulation is stopped. Once the nerve is found, two tiny, sterile, microelectrodes will be inserted through the skin. One is a reference electrode placed just above the nerve site (2 cm) and the other is the recording electrode. The recording electrode is advanced into the nerve. When the tip of the electrode enters the nerve, the subject may briefly notice either pressure or tingling sensations. At this point, minor adjustments in the position of the electrode will be made until an optimal nerve signal is obtained.

Limb Blood Flow Measurements- Blood flow to the arm or leg may also be measured by using duplex Doppler ultrasound to non-invasively measure mean arterial blood velocity and diameter. Femoral or brachial blood velocity can be obtained by placing a Doppler flow probe on the skin over the common femoral artery distal to the inguinal ligament or the brachial artery, respectively. Ultrasound imaging of femoral artery or brachial artery diameter will be performed at a site matching that at which velocity is measured. The following formula is used to calculate blood flow: blood flow = π * radius2 * velocity.

Urine samples will be collected to measure specific gravity and pH using test strips.

Experimental Procedures:

Neck Pressure and Neck Suction- A padded neck collar will be fitted around the anterior portion of the subject's neck for the application of brief 5-second periods of neck pressure and neck suction. This allows the application of positive or negative pressure to the carotid sinus baroreceptors which are located in this region. The positive pressure will transiently cause these receptors to detect a decrease in blood pressure and thus cause an acute increase in heart rate, and blood pressure. The negative pressure will transiently cause these receptors to detect an increase in blood pressure and thus cause an acute decrease in heart rate, and blood pressure. This procedure has been used extensively to non-invasively assess baroreflex function in healthy subjects aged between 18-80 years. Nevertheless, in subjects over 50 years of age Doppler imaging will be performed to screen for atherosclerotic plaques within the carotid vessels to rule out carotid artery disease and determine the feasibility of performing neck pressure and neck suction.

Handgrip Exercise and Post Exercise Ischemia- The subject will be asked to perform handgrip exercise for either two minutes or until they feel like they cannot maintain the exercise (i.e., fatigue). Five seconds before stopping the exercise, a cuff around the upper arm will be inflated to impede blood flow for 2 minutes. This traps the metabolites that were produced during the exercise in the area of the muscle, which maintains stimulation of skeletal muscle metaboreceptor afferents. Since these metaboreceptor afferents contribute to the rise in blood pressure during exercise, continued stimulation of these receptors maintains a blood pressure response.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • We plan to study female subjects of all ethnic backgrounds ranging in age from 18 to 80 years. Only healthy, normotensive individuals not taking medications will be included in this study.
  • All postmenopausal women will be at least 4 years post menopause to avoid the potential for perimenopausal interference with study results

Exclusion Criteria:

  • Active cardiopulmonary disease
  • Hypertension
  • Diabetes
  • COPD with concurrent daily use of inhalers.
  • Known liver disease
  • Peripheral neuropathy
  • Chronic Kidney disease
  • Pregnant women
  • Any of the following contraindications to estrogen usage will cause exclusion:
  • Personal or 1st degree relative (mother, sister, daughter) history of breast, ovarian, or uterine cancer
  • Vaginal bleeding;
  • Current thrombophlebitis or venous thromboembolic disorders including deep vein thrombosis or pulmonary embolus;
  • Arterial thromboembolic disease such as stroke or myocardial infarction
  • Migraine headaches
  • Any previous intolerance to estrogen supplementation.
  • Women who have smoked during the one-year period prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01633814

Locations
United States, Missouri
University of Missouri Recruiting
Columbia, Missouri, United States, 65212
Contact: Charla L Jay, BSN    573-884-5048    jayc@health.missouri.edu   
Contact: Paul J Fadel    573-884-5220    fadelp@health.missouri.edu   
Principal Investigator: Paul J Fadel, PhD         
Sponsors and Collaborators
University of Missouri-Columbia
Investigators
Principal Investigator: Paul J Fadel, PhD University of Missouri-Columbia
  More Information

No publications provided

Responsible Party: Paul Fadel, PhD, Associate Professor, University of Missouri-Columbia
ClinicalTrials.gov Identifier: NCT01633814     History of Changes
Other Study ID Numbers: 1133919
Study First Received: June 25, 2012
Last Updated: June 25, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Estradiol
Polyestradiol phosphate
Hormones
Progesterone
Estradiol valerate
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estrogens
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Contraceptive Agents
Reproductive Control Agents
Therapeutic Uses
Contraceptive Agents, Female
Progestins

ClinicalTrials.gov processed this record on August 26, 2014